Published in
American Society of Hematology, Blood Advances, 5(1), p. 319-329, 2017
DOI: 10.1182/bloodadvances.2016000943
Links
Tools
Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia
Journal article published in 2017 by
Judith Reina-Castillón,
Roser Pujol,
Marcos López-Sánchez,
Benjamín Rodríguez-Santiago,
Miriam Aza-Carmona,
Juan Ramón González,
José Antonio Casado 
,
Juan Antonio Bueren,
Julián Sevilla,
Isabel Badel,
Albert Català,
Cristina Beléndez,
María Ángeles Dasí,
Cristina Díaz de Heredia ,
Jean Soulier
and other authors.
,
Juan Antonio Bueren,
Julián Sevilla,
Isabel Badel,
Albert Català,
Cristina Beléndez,
María Ángeles Dasí,
Cristina Díaz de Heredia ,
Jean Soulier
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Fanconi anemia patients have exacerbated cytogenetic clonal mosaicism as detected by molecular karyotyping of blood DNA with SNP assays. Bone marrow clonal abnormalities can be detected in blood DNA and used as biomarkers of cancer risk and poor prognosis.